Author

Rose Vaughan

INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL REMISSION AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIAL SUBSTUDY RESULTS BY LINE OF TREATMENT AND LOCATION
INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL REMISSION AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIAL SUBSTUDY RESULTS BY LINE OF TREATMENT AND LOCATION

Rose Vaughan  et al.

USTEKINUMAB DRUG EXPOSURE IS NOT LINKED TO CHANGES IN BOWEL WALL THICKNESS, BUT DOES ASSOCIATE WITH TRANSMURAL REMISSION IN CROHN’S DISEASE
USTEKINUMAB DRUG EXPOSURE IS NOT LINKED TO CHANGES IN BOWEL WALL THICKNESS, BUT DOES ASSOCIATE WITH TRANSMURAL REMISSION IN CROHN’S DISEASE

Rose Vaughan  et al.

Item 1 - 2 / 2
1